Welcome to BeiMedPlus

Professor Tam discusses some common chronic lymphocytic leukemia (CLL) disease characteristics and expected treatment outcomes. He introduces the role of Bruton's tyrosine kinase inhibition (BTKi) in CLL, challenges in their use, and hopes for the future treatment of CLL.

BeiGene wants to ensure access to medicines for all patients and puts patients first in the fight against cancer. We foster strong collaborations that extend to the farthest reaches of the globe. Learn more about the BeiGene story.

The panel answers questions from the audience at the ESH 2021 satellite symposium providing insight into treatment considerations with different Bruton's tyrosine kinase inhibitors (BTKis) for Waldenström's macroglobulinemia (WM) patients.